Pivotal bioVenture Partners Investment Advisor LLC
CIK 0001844645 · SAN FRANCISCO, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$307.8M
2026 Q2
Positions
13
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
95.1%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
PCVX
VAXCYTE INC
26.9%
ARQT
ARCUTIS BIOTHERAPEUTICS INC
10.8%
TRVI
TREVI THERAPEUTICS INC
10.6%
AVLN
AVALYN PHARMACEUTICALS INC
10.3%
EVMN
EVOMMUNE INC
8.3%
MPLT
MAPLIGHT THERAPEUTICS INC
7.1%
OCS
OCULIS HOLDING AG
6.8%
BIOA
BIOAGE LABS INC
5.2%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.